Latest Kaiser Health News Stories
Several major drugmakers vow to contain drug prices, but similar pledges since the 1990s have not had much impact.
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Margot Sanger-Katz of The New York Times, Joanne Kenen of Politico, and Erin Mershon of Stat News discuss a series of health policy court decisions on everything from prescription drug discounts to soda taxes. Plus, Rovner, interviews health care futurist and consultant Jeff Goldsmith.
Some state Medicaid programs are not paying for the procedures, and Medicare’s complicated payment rates have hospitals concerned that it will not cover all the costs.
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
The vaccine, BCG, is relatively cheap. But experts caution the therapy could be overhyped and, if proven effective, wind up overpriced.
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Margot Sanger-Katz of The New York Times, Anna Edney of Bloomberg News and Julie Appleby of Kaiser Health News discuss the health politics of the latest Supreme Court pick, as well as the Trump administration’s efforts to further undermine the Affordable Care Act. Plus, for extra credit, the panelists recommend their favorite health stories of the week.
Other readers ask what can be done to challenge unexpected medical bills — whether the result of an emergency room visit or after a change in prescription drug coverage.
A survey of 49 states reveals that an estimated 144,000 inmates with hepatitis C, a curable but potentially fatal disease, can’t get the expensive drugs they need to cure it.
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Joanne Kenen of Politico, Stephanie Armour of The Wall Street Journal and Anna Edney of Bloomberg News discuss the latest enrollment numbers for the Affordable Care Act, Medicaid work requirements in Kentucky and President Donald Trump’s proposed government reorganization plan. Plus, for extra credit, the panelists recommend their favorite health stories of the week.
It’s getting increasingly difficult for patients to afford Truvada, also known as pre-exposure prophylaxis, or PrEP, because of the drug’s high price and insurance company efforts to restrict the use of coupons that shield patients from it.
Newsletter editor Brianna Labuskes, who reads everything on health care to compile our daily Morning Briefing, offers the best and most provocative stories for the weekend.
As part of his plan to tamp down drug pricing, President Donald Trump wants pharmaceutical companies to provide cost information in drug ads — just like side effects.
Sometimes a drug plan’s copayment is higher than the cash price, and under a little-known federal rule, pharmacists have to tell Medicare beneficiaries that — but only if they ask.
More health plans are refusing to count the copayment assistance offered by drug makers as part of the patients’ deductibles or out-of-pocket limits.
KHN’s newsletter editor, Brianna Labuskes, wades through hundreds of health articles from the week so you don’t have to.
The drugmaker agreed to a settlement with the Justice Department over allegations that it funneled copay assistance money through a foundation to Medicare patients.
KHN’s Sarah Jane Tribble explains the key elements of the Trump blueprint on CBS News’ “Red & Blue.”